Brokerages set USD 45.17 target for Indivior stock

Published on 10/17/2026 at 19:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 343.00 million on June 30, 2026. Indivior stock was USD 32.45 on October 16, 2026, down 3.48 percent on Nasdaq.

Coverage and valuation

Seven research firms held a Buy consensus on October 15, 2026.
Second-quarter revenue reached USD 343.00 million on June 30, 2026.
Indivior stock last stood at USD 32.45 on October 16, 2026 at 4:00 p.m. ET, down 3.48 percent on Nasdaq versus USD 33.62.
Market capitalization was USD 4.0 billion and the price-to-earnings ratio was 11.63 on October 16, 2026.

Moderne Pharma-Produktionsanlage mit Glasfassade und Industrieanlagen im Tageslicht — Indivior PLC mit ISIN GB00BYZ0C031 betreibt moderne Pharma-Produktionsanlage für innovative Suchtmedizin-Präparate weltweit an Patienten, Illustration mit AI erstellt.

Brokerages put a USD 45.17 12-month consensus target on Indivior stock (ISIN US45579U1097), according to MarketBeat on October 15, 2026. Seven research firms carried a Buy consensus, and the target stood 39.20 percent above the latest Nasdaq price in the same currency. Indivior was last at USD 32.45 on October 16, 2026 at 4:00 p.m. ET, down 3.48 percent on Nasdaq from USD 33.62.

Revenue sets the operating reference

Indivior reported second-quarter revenue of USD 343.00 million for the quarter ended June 30, 2026, according to MarketBeat. The figure gives the stock report an operating anchor alongside the broker target, while the share price remained below its recent yearly high.

Price position stays measurable

MarketBeat reported a one-year trading range of USD 23.72 to USD 42.81 on October 15, 2026. The latest Nasdaq price of USD 32.45 therefore remained inside that range, with the high and low providing the relevant boundaries for the market move.

Valuation and the next date

Indivior had a market capitalization of USD 4.0 billion and a price-to-earnings ratio of 11.63 as of October 16, 2026. The company is a specialty pharmaceutical business focused on treatments for substance use disorders and serious mental health conditions. MarketBeat listed October 30, 2026 as the record date for the special dividend and November 6, 2026 as the payment date.

Comparison with peers

Indivior (Nasdaq, USD): minus 3.48 percent, P/E 11.63, market capitalization USD 4.0 billion.
Collegium Pharmaceutical (Nasdaq, USD): plus 0.04 percent, P/E 18.70, market capitalization USD 755.0 million.
Alkermes (Nasdaq, USD): plus 2.79 percent, P/E 107.62, market capitalization USD 6.9 billion.

Nasdaq price and market frame

The Nasdaq quotation places Indivior at USD 32.45 on October 16, 2026 at 4:00 p.m. ET, down 3.48 percent from the prior close of USD 33.62. The valuation, trading range and analyst target provide the main reference points for the next session.